RICHMOND, Calif., Aug. 5 /PRNewswire-FirstCall/ -- Sangamo BioSciences,
Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president
and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic
development programs and an overview of the company's business strategy at
4:30 p.m. (ET) on Tuesday, August 12, 2008, at the 28th Canaccord Adams Global
Growth Conference in Boston.
The presentation will be webcast live and may be accessed via a link on
the Sangamo BioSciences website in the Investor Relations section
http://investor.sangamo.com/index.cfm under Events and Presentations. The
presentation will be archived on the Sangamo website for two weeks after the
event.
About Sangamo
Sangamo BioSciences, Inc. is focused on the research and development of
novel DNA-binding proteins for therapeutic gene regulation and modification.
The most advanced ZFP Therapeutic(TM) development program is currently in
Phase 2 clinical trials for evaluation of safety and clinical effect in
patients with diabetic neuropathy. Other therapeutic development programs are
focused on stem cell mobilization, ALS, cancer, HIV/AIDS, neuropathic pain,
nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's
core competencies enable the engineering of a class of DNA-binding proteins
known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that
recognize a specific DNA sequence Sangamo has created ZFP transcription
factors (ZFP TF(TM)) that can control gene expression and, consequently, cell
function. Sangamo is also developing sequence-specific ZFP Nucleases
(ZFN(TM)) for gene modification. Sangamo has established strategic
partnerships with companies outside of the human therapeutic space including
Dow AgroSciences, Sigma-Aldrich and several companies applying its ZFP
Technology to enhance the production of protein pharmaceuticals. For more
information about Sangamo, visit the company's web site at www.sangamo.com.
This press release may contain forward-looking statements based on
Sangamo's current expectations. These forward-looking statements include,
without limitation, references to the research and development of novel ZFP
TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology
platform, strategic partnerships with collaborators and clinical trials of ZFP
Therapeutics. Actual results may differ materially from these forward-looking
statements due to a number of factors, including technological challenges,
uncertainties relating to the initiation and completion of stages of ZFP
Therapeutic clinical trials, Sangamo's ability to develop commercially viable
products and technological developments by our competitors. See the company's
SEC filings, and in particular, the risk factors described in the company's
Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q.
Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking
information contained in this press release.
SOURCE Sangamo BioSciences, Inc.
